Skip to main content

IL‐1ra serum levels in disease stagesof MS – a marker for progression?

Buy Article:

$51.00 plus tax (Refund Policy)


Interleukin‐1 (IL‐1) is one of the major proinflammatory cytokines expressed consistently in multiple sclerosis (MS) lesions. Interleukin‐1 receptor antagonist (IL‐1ra) is the only known naturally occurring specific antagonistic cytokine counteracting IL‐1. Thus IL‐1ra may have a downregulating potential in the disease course of MS. We analysed if circulating IL‐1ra could be associated with different disease stages of MS in sera of 84 MS patients and 18 controls. IL‐1ra showed considerable variations in MS patients and controls. Nevertheless we found significantly elevated serum levels in active as well as in stable disease stages compared to controls. IL‐1ra levels were higher in progressive disease courses compared to relapsing–remitting MS, but not statistically significant (median: 516 versus 434 pg/ml). Further analysis with larger groups of patients and longitudinal studies will clarify if IL‐1ra is useful as a prognostic serum marker in MS.

Keywords: cytokines; inflammatory neurological disease; interleukin‐1 receptor antagonist; multiple sclerosis

Document Type: Original Article


Publication date: February 1, 2000

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more